RxDoctor Payments Data

Anneyamma Mannancheril, MD

Hematology-Oncology · White Plains, NYNPI 1841297702

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $385, more than ten times the $25 reported in 2019.

$969in general payments, 2019–2025

Across 47 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$229
  • Johnson & Johnson$124
  • Novartis$81
  • Incyte Corporation$58
  • Gilead$58
  • AVEO Pharmaceuticals, Inc.$43
  • plus $376 from 15 others

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$969 in reported general payments places this provider in the 75th percentile of 38 hematology-oncology providers in New York.

See all hematology-oncology providers in New York

Medicare billing

Part B allowed, 2024
$74,447
Medicare patients
169
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib24$389,185
Imatinib Mesylate13$136,528
EliquisApixaban65$48,759
XareltoRivaroxaban47$37,484
Hydroxyurea20$405
Warfarin Sodium43$315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$33$437,94589 claims
Johnson & JohnsonXarelto$124$37,48447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 38 hematology-oncology providers in New York.

Other hematology-oncology in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →